Brookings Releases Framework Clarifying Drug Decriminalization Debates

Framework Separates Possession From Distribution Models

The Brookings paper distinguishes between possession-only decriminalization and broader models that permit regulated sales. Most public debates conflate two separate things: removing criminal penalties for personal use and creating legal commercial markets. That's the cleanest read on the current policy confusion.

The framework identifies three distinct policy tiers: criminal penalties with incarceration, civil penalties without jail time, and full legalization with regulated commerce. Most state ballot measures since 2020 have mixed elements from all three tiers. The result? Operational ambiguity for law enforcement and regulators.

Oregon Rollback Drives New Policy Scrutiny

Oregon's 2024 repeal of Measure 110 has intensified national debate over decriminalization efficacy. The state legislature voted in April 2024 to restore misdemeanor charges for drug possession after a three-year experiment with civil citations and treatment referrals.

Brookings researchers note that Oregon's model lacked the treatment infrastructure and enforcement mechanisms that Portugal's decriminalization system relies on. The paper doesn't endorse or oppose decriminalization but argues that policy design details determine outcomes more than the binary choice between criminal and civil penalties.

Cannabis Decriminalization Versus Legalization

Twenty-four states have decriminalized cannabis possession without legalizing retail sales, creating a patchwork of enforcement practices. Decriminalization alone doesn't address illicit market supply chains or generate tax revenue for prevention programs, the Brookings framework highlights.

States including Virginia and Minnesota decriminalized possession years before launching licensed retail markets. That lag period created gray-market growth. It complicated subsequent regulatory rollouts, according to the paper.

Psychedelics Policy Enters Similar Terrain

Colorado and Oregon have enacted psilocybin therapy programs that decriminalize possession within licensed settings but maintain criminal penalties for unauthorized distribution. The Brookings analysis categorizes these hybrid models as distinct from both full prohibition and broad decriminalization.

Massachusetts voters will decide in November 2026 whether to approve a similar psilocybin therapy framework. The ballot language mirrors Colorado's regulated-access model rather than Oregon's Measure 110 approach.

Federal Scheduling Remains the Anchor Variable

The paper notes that federal Schedule I classification limits state decriminalization experiments by maintaining criminal liability under the Controlled Substances Act. Cannabis rescheduling to Schedule III, if finalized by DEA, wouldn't decriminalize possession under federal law but would reduce certain penalties and eliminate 280E tax burdens for state-licensed operators.

State decriminalization policies operate in legal tension with federal prohibition, creating enforcement discretion gaps that vary by jurisdiction and administration.

Treatment Capacity Emerges as Policy Bottleneck

Brookings identifies insufficient treatment infrastructure as the common failure point in decriminalization experiments. Oregon's Measure 110 allocated cannabis tax revenue to treatment expansion, but capacity lagged demand by an estimated 60 percent in the program's first two years.

States considering decriminalization should fund treatment and harm-reduction services at least two years before removing criminal penalties, the paper recommends. That sequencing hasn't occurred in any U.S. jurisdiction to date.

What This Means for State Policy Design

The Brookings framework will likely inform legislative debates in states drafting 2027 cannabis and psychedelics bills. Policymakers now have a taxonomy. It separates possession decriminalization from commercial legalization and regulated therapy access. For full background on this story, see the CannIntel topic hub on drug decriminalization policy.

Minnesota offers the next legislative test, where lawmakers are debating whether to decriminalize psilocybin possession statewide or limit access to licensed therapy centers. The bill language will signal which model the state considers more viable.